Olivier Kosmider
Reproducibility track record
1
assessed papers
32/100
mean reproducibility
0
reproduced (C1–C2)
1
flagged
0
total citations
flag rate:
100%
(1/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Guilhem Clary 1Elissa Khadra 1Didier Bouscary 1Justine Decroocq 1Charles Dussiau 1Morgane Le Gall 1Michaëla Fontenay 1Nicolas Chapuis 1Zubaidan Tuerdi 1Françoise Levavasseur 1
Institutions
Centre National de la Recherche Scientifique 1Inserm 1Université Paris Cité 1Institut Cochin 1Acute Leukemia French Association 1Fondation pour la Recherche Médicale 1
Geography (author institutions)
FR 1DE 1CH 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (461)
Request a reproduction →1 assessed by us (0 reproduced) · 460 not yet assessed — every PubMed paper on record, linked below.
-
The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report ↗Case Reports in Hematology · 2026 · PMID 42136818not yet assessed
-
Characterization and Outcomes of Patients with Systemic Mastocytosis with Associated Lymphoid Neoplasms: An ECNM-CEREMAST Study ↗SSRN Electronic Journal · 2026not yet assessed
-
Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome ↗Lara D. Veeken · 2026 · PMID 41999206not yet assessed
-
High frequency of <scp>CD95</scp> <sup>+</sup> / <scp>CD45RA</scp> <sup>−</sup> regulatory T cells defines an immunosuppressive profile associated with <scp>MDS</scp> progression ↗British Journal of Haematology · 2026 · PMID 42080308not yet assessed
-
American College of Rheumatology (ACR) guidance for diagnosis and management of VEXAS ↗La Revue de Médecine Interne · 2026not yet assessed
-
Apport de la courbe réactionnelle du TCA-Synthasil dans le dépistage des anticoagulants circulants ↗2026not yet assessed
-
Inflammatory cell death and monocyte dysfunction in VEXAS syndrome ↗Blood · 2026 · PMID 41770812not yet assessed
-
Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome ↗Leukemia · 2026 · PMID 41545701not yet assessed
-
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX ↗Blood · 2025 · PMID 40373272not yet assessed
-
American College of Rheumatology Guidance Statement for Diagnosis and Management of <scp>VEXAS</scp> Developed by the International <scp>VEXAS</scp> Working Group Expert Panel ↗Arthritis & Rheumatology · 2025 · PMID 40787890not yet assessed
-
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome ↗Blood · 2025 · PMID 40729686not yet assessed
-
Neurological manifestations in patients with VEXAS syndrome ↗Journal of Neurology · 2025 · PMID 39891740not yet assessed
-
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With <scp>VEXAS</scp> Syndrome: An International Multicenter Study ↗Arthritis & Rheumatology · 2025 · PMID 40977434not yet assessed
-
VEXAS anemia is a mosaic erythroblastopenia ↗Blood · 2025 · PMID 40971475not yet assessed
-
Characterizing VEXAS syndrome in women: Findings from an international multicenter study ↗Journal of Internal Medicine · 2025 · PMID 40985189not yet assessed
-
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes ↗HemaSphere · 2025 · PMID 39850648not yet assessed
-
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score ↗Blood · 2025 · PMID 40561337not yet assessed
-
Orchestration of human multi‐lineage hematopoietic cell development by humanized in vivo bone marrow models ↗HemaSphere · 2025 · PMID 40265169not yet assessed
-
Very long-term remission with azacitidine in VEXAS syndrome ↗Haematologica · 2025 · PMID 39882650not yet assessed
-
Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors ↗HemaSphere · 2025 · PMID 41306328not yet assessed
-
Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM) ↗HemaSphere · 2025 · PMID 40201745not yet assessed
-
[VEXAS Syndrome]. ↗PubMed · 2025 · PMID 40476413not yet assessed
-
UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025not yet assessed
-
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine ↗HemaSphere · 2025 · PMID 39760001not yet assessed
-
Pro-inflammatory role of granzyme K producing bystander CD8 <sup>+</sup> T cells in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025not yet assessed
-
MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION ↗Leukemia Research · 2025not yet assessed
-
Rôle de la mort cellulaire médiée par RIPK1 et défaut de réponse aux signaux de danger au cours du syndrome VEXAS ↗La Revue de Médecine Interne · 2025not yet assessed
-
Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome ↗Blood · 2025not yet assessed
-
Non-coding variants in UBA1 lead to vexas ↗Blood · 2025not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑Communications Biology · 2025 · PMID 41407883L1 32/100 ⚑
-
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation ↗Nature Communications · 2024 · PMID 38291039not yet assessed
-
Molecular taxonomy of myelodysplastic syndromes and its clinical implications ↗Blood · 2024 · PMID 38958467not yet assessed
-
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX ↗Annals of the Rheumatic Diseases · 2024 · PMID 38777378not yet assessed
-
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes ↗Blood · 2024 · PMID 38687605not yet assessed
-
Shared and distinct mechanisms of UBA1 inactivation across different diseases ↗The EMBO Journal · 2024 · PMID 38360993not yet assessed
-
Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France ↗The Lancet Digital Health · 2024 · PMID 38670741not yet assessed
-
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond ↗The Lancet Haematology · 2024 · PMID 38302223not yet assessed
-
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models ↗Science Translational Medicine · 2024 · PMID 39047119not yet assessed
-
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation ↗Nature Communications · 2024 · PMID 38589367not yet assessed
-
Involvement of the <scp>JAK</scp>‐<scp>STAT</scp> pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide <scp>CEREO</scp> study ↗American Journal of Hematology · 2024 · PMID 38563187not yet assessed
-
Nonischemic Cardiac Manifestations in VEXAS Syndrome ↗JAMA Network Open · 2024 · PMID 39666342not yet assessed
-
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents ↗Blood Cancer Journal · 2024 · PMID 39112451not yet assessed
-
A Clinicopathological Description of Kidney Features in VEXAS Syndrome ↗Kidney International Reports · 2024 · PMID 39810778not yet assessed
-
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort ↗Blood · 2024 · PMID 39571148not yet assessed
-
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms ↗Leukemia · 2024 · PMID 38575672not yet assessed
-
Trismus as a new feature of VEXAS syndrome ↗Lara D. Veeken · 2024 · PMID 38450422not yet assessed
-
Comparison of prognostic scores according to <scp>WHO</scp> classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin ↗American Journal of Hematology · 2024 · PMID 39287048not yet assessed
-
Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome ↗bioRxiv (Cold Spring Harbor Laboratory) · 2024not yet assessed
-
not yet assessed
-
VEXAS anemia is a mosaic erythroblastopenia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2024not yet assessed
-
not yet assessed
-
Humanized <i>in vivo</i> bone marrow models orchestrate multi-lineage human hematopoietic cell development ↗bioRxiv (Cold Spring Harbor Laboratory) · 2024not yet assessed
-
Deep Learning‐Based Blood Abnormalities Detection as a Tool for <scp>VEXAS</scp> Syndrome Screening ↗International Journal of Laboratory Hematology · 2024 · PMID 39275905not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Signification clinique des gammapathies monoclonales au cours du syndrome VEXAS ↗La Revue de Médecine Interne · 2024not yet assessed
-
Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort ↗Blood · 2024not yet assessed
-
Erratum for Barbosa Bomfim et al., “CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients” ↗Journal of Virology · 2024 · PMID 39655958not yet assessed
-
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in <i>FLT3</i> -Mutant Leukemia ↗Cancer Discovery · 2023 · PMID 37012202not yet assessed
-
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry ↗Annals of the Rheumatic Diseases · 2023 · PMID 38071510not yet assessed
-
Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein ↗Cell Death Discovery · 2023 · PMID 36928207not yet assessed
-
Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome ↗HemaSphere · 2023 · PMID 36999004not yet assessed
-
FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells ↗Blood Advances · 2023 · PMID 36930820not yet assessed
-
The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms ↗Kidney International · 2023 · PMID 37769965not yet assessed
-
Very short insertions in the <i>FLT3</i> gene are of therapeutic significance in acute myeloid leukemia ↗Blood Advances · 2023 · PMID 37987760not yet assessed
-
Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France ↗HemaSphere · 2023 · PMID 37637995not yet assessed
-
The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots ↗Human Mutation · 2023 · PMID 40225169not yet assessed
-
Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study ↗British Journal of Haematology · 2023 · PMID 37403204not yet assessed
-
SMD & LMMC : diagnostic et classification ↗Bulletin du Cancer · 2023 · PMID 37453834not yet assessed
-
VEXAS: is it time to reshape the nosology of clonal hematopoiesis? ↗Expert Review of Hematology · 2023 · PMID 37119011not yet assessed
-
Caractéristiques cliniques et biologiques du syndrome VEXAS selon le sexe : comparaison de 12 femmes françaises à 274 hommes ↗La Revue de Médecine Interne · 2023not yet assessed
-
Efficacité et tolérance de l’azacitidine au cours du syndrome VEXAS avec et sans syndrome myélodysplasique : données du registre français ↗La Revue de Médecine Interne · 2023not yet assessed
-
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023 · PMID 37873213not yet assessed
-
not yet assessed
-
Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms ↗Blood · 2023not yet assessed
-
Corrigendum to: Entropy as a measure of variability and stemness in single-cell transcriptomics ↗Current Opinion in Systems Biology · 2023not yet assessed
-
Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening ↗Blood · 2023not yet assessed
-
<i>UBA1</i> Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes ↗Blood · 2023not yet assessed
-
not yet assessed
-
Genotype-Phenotype Mapping Via Single-Cell Multi-Omics Identifies Therapeutic Vulnerabilities in Vexas Syndrome ↗Blood · 2023not yet assessed
-
not yet assessed
-
Recherche systématique de la mutation UBA1 chez les hommes après un premier épisode thrombotique veineux ↗JMV-Journal de Médecine Vasculaire · 2023not yet assessed
-
Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study ↗Haematologica · 2023 · PMID 36994502not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes ↗Cancer Research · 2023not yet assessed
-
not yet assessed
-
Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION ↗Leukemia Research · 2023not yet assessed
-
Systematic search for the UBA1 mutation in men after a first venous thrombotic episode ↗Archives of Cardiovascular Diseases Supplements · 2023not yet assessed
-
Apport de la tomographie par émission de positrons (TEP) au cours du syndrome VEXAS ↗La Revue de Médecine Interne · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Efficacité et tolérance des thérapies ciblées au cours du syndrome VEXAS : étude rétrospective du groupe français VEXAS sur 110 patients ↗La Revue de Médecine Interne · 2023not yet assessed
-
Un syndrome VEXAS chez une femme sans monosomie X ↗La Revue de Médecine Interne · 2023not yet assessed
-
Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia ↗Blood · 2023not yet assessed
-
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes ↗NEJM Evidence · 2022 · PMID 38319256not yet assessed
-
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML ↗Leukemia · 2022 · PMID 36104395not yet assessed
-
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients ↗RMD Open · 2022 · PMID 35868738not yet assessed
-
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study ↗Blood · 2022 · PMID 35443031not yet assessed
-
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases ↗Journal of the American Academy of Dermatology · 2022 · PMID 36343774not yet assessed
-
Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome ↗CHEST Journal · 2022 · PMID 36272567not yet assessed
-
VEXAS Syndrome: A Novelty in MDS Landscape ↗Diagnostics · 2022 · PMID 35885496not yet assessed
-
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients ↗Blood Cancer Journal · 2022 · PMID 36055992not yet assessed
-
Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level ↗BMC Biology · 2022 · PMID 35260165not yet assessed
-
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia ↗Leukemia · 2022 · PMID 35354920not yet assessed
-
Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: A monocentric study ↗Journal of Thrombosis and Haemostasis · 2022 · PMID 36002395not yet assessed
-
Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning ↗Haematologica · 2022 · PMID 35199507not yet assessed
-
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases ↗Clinical and Experimental Medicine · 2022 · PMID 35953763not yet assessed
-
The Mesenchymal Niche in Myelodysplastic Syndromes ↗Diagnostics · 2022 · PMID 35885544not yet assessed
-
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes ↗Annals of Hematology · 2022 · PMID 36195681not yet assessed
-
<i>Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation</i> ↗Blood · 2022not yet assessed
-
Acquired spherocytosis due to somatic <scp><i>ANK1</i></scp> mutations as a manifestation of clonal hematopoiesis in elderly patients ↗American Journal of Hematology · 2022 · PMID 35560067not yet assessed
-
<scp>TP53</scp> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia ↗American Journal of Hematology · 2022 · PMID 35083778not yet assessed
-
<i>Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS</i> ↗Blood · 2022not yet assessed
-
<scp>PCR‐Fluo‐<i>ASXL1</i>‐FA</scp>: A fast, sensitive and inexpensive complementary method to detect <scp><i>ASXL1</i></scp> mutations in haematological malignancies ↗International Journal of Laboratory Hematology · 2022 · PMID 35793805not yet assessed
-
VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation ↗medRxiv · 2022not yet assessed
-
C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2022not yet assessed
-
VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation ↗SSRN Electronic Journal · 2022not yet assessed
-
not yet assessed
-
Corrigendum to Ronsin C, Benard L, Kosmider O, et al. Acute tubulointerstitial nephritis revealing VEXAS syndrome. Kidney Int. 2022;101:1295–1297 ↗Kidney International · 2022 · PMID 36150769not yet assessed
-
DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with <i>SF3B1</i> Mutation ↗Blood · 2022not yet assessed
-
Vacuoles au sein des précurseurs myéloïdes médullaires dans le syndrome VEXAS : seuil et performances diagnostiques ↗La Revue de Médecine Interne · 2022not yet assessed
-
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients* ↗British Journal of Dermatology · 2021 · PMID 34632574not yet assessed
-
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗Haematologica · 2021 · PMID 33406814not yet assessed
-
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry ↗British Journal of Haematology · 2021 · PMID 34651299not yet assessed
-
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of <i>ASXL1</i> mutations: a FIM study ↗Blood Advances · 2021 · PMID 33666653not yet assessed
-
Atypical splice-site mutations causing VEXAS syndrome ↗Lara D. Veeken · 2021 · PMID 34213531not yet assessed
-
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold ↗British Journal of Haematology · 2021 · PMID 34340250not yet assessed
-
Entropy as a measure of variability and stemness in single-cell transcriptomics ↗Current Opinion in Systems Biology · 2021not yet assessed
-
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes ↗Blood Advances · 2021 · PMID 33890980not yet assessed
-
Severe Joint Involvement in VEXAS Syndrome: A Case Report ↗Annals of Internal Medicine · 2021 · PMID 33780294not yet assessed
-
Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case–control and exploratory study ↗Lara D. Veeken · 2021 · PMID 33836046not yet assessed
-
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis ↗Blood Cancer Journal · 2021 · PMID 33741892not yet assessed
-
Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies ↗European Journal of Cancer · 2021 · PMID 34700215not yet assessed
-
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin ↗Haematologica · 2021 · PMID 34320786not yet assessed
-
Reticulocytosis As a Whistleblower: A Rare Case of Acquired Elliptocytosis in a Myelodysplastic Syndrome Patient With Trisomy 8 ↗HemaSphere · 2021 · PMID 33458593not yet assessed
-
Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement ↗Anti-Cancer Drugs · 2021 · PMID 34145177not yet assessed
-
Observatoire français de 116 patients avec un syndrome VEXAS : corrélation phénotype–génotype et prise en charge ↗La Revue de Médecine Interne · 2021not yet assessed
-
Quand la PAN devient VEXAS ↗La Revue de Médecine Interne · 2021not yet assessed
-
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗Nature Medicine · 2021not yet assessed
-
Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry ↗Blood · 2021not yet assessed
-
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗Nature Medicine · 2021 · PMID 33564192not yet assessed
-
Hematopoietic differentiation is characterized by a transient peak of entropy at a single cell level ↗bioRxiv (Cold Spring Harbor Laboratory) · 2021not yet assessed
-
Quand la génétique permet d’expliquer 14 ans de phénomènes inflammatoires ↗La Revue de Médecine Interne · 2021not yet assessed
-
Utilisation de l’azacitidine dans le VEXAS chez des patients porteurs d’un syndrome myélodysplasique : données du registre Français VEXAS ↗La Revue de Médecine Interne · 2021not yet assessed
-
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 ↗Cell · 2020 · PMID 32810439not yet assessed
-
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗Nature Medicine · 2020 · PMID 32747829not yet assessed
-
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML ↗European Journal Of Haematology · 2020 · PMID 32659848not yet assessed
-
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia ↗Oncogenesis · 2020 · PMID 33093450not yet assessed
-
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study ↗Leukemia · 2020 · PMID 32684630not yet assessed
-
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide ↗British Journal of Haematology · 2020 · PMID 32147816not yet assessed
-
Multicenter Next-Generation Sequencing Studies between Theory and Practice ↗Journal of Molecular Diagnostics · 2020 · PMID 33359455not yet assessed
-
Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome ↗Annals of Hematology · 2020 · PMID 32533252not yet assessed
-
Coagulation Characterization of Prothrombin 20209C > T Variant: About 27 New Cases ↗Thrombosis and Haemostasis · 2020 · PMID 32932543not yet assessed
-
Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy ↗Leukemia & lymphoma/Leukemia and lymphoma · 2020 · PMID 32856491not yet assessed
-
not yet assessed
-
Séquençage à haut débit et hémopathies myéloïdes ↗Revue de biologie médicale. · 2020not yet assessed
-
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups ↗Leukemia · 2019 · PMID 30635634not yet assessed
-
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia ↗Leukemia · 2019 · PMID 30894665not yet assessed
-
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib <i>via</i> STAT5-and hypoxia-dependent upregulation of AXL ↗Haematologica · 2019 · PMID 30923103not yet assessed
-
Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes ↗Blood Advances · 2019 · PMID 31869414not yet assessed
-
A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome ↗Science Translational Medicine · 2019 · PMID 31292266not yet assessed
-
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer ↗Proceedings of the National Academy of Sciences · 2019 · PMID 30867289not yet assessed
-
Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin ↗Cell Reports · 2019 · PMID 30893598not yet assessed
-
Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1‐tube panel strategy for diagnosis and prognosis of patients with MDS ↗Cytometry Part B Clinical Cytometry · 2019 · PMID 31498561not yet assessed
-
The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes ↗Cytometry Part B Clinical Cytometry · 2019 · PMID 30963682not yet assessed
-
Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer ↗The Annals of Thoracic Surgery · 2019 · PMID 31408646not yet assessed
-
Accreditation strategy for rare somatic molecular abnormalities detected or quantified by polymerase chain reaction: GBMHM recommendations ↗Annales de biologie clinique · 2019 · PMID 31859645not yet assessed
-
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study ↗British Journal of Haematology · 2019 · PMID 31215036not yet assessed
-
Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence? ↗Blood Cells Molecules and Diseases · 2019 · PMID 31794934not yet assessed
-
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes ↗Blood · 2019not yet assessed
-
Implications of <i>TP53</i> Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes ↗bioRxiv (Cold Spring Harbor Laboratory) · 2019not yet assessed
-
not yet assessed
-
The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants ↗Blood · 2019not yet assessed
-
not yet assessed
-
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents ↗EBioMedicine · 2018 · PMID 29728305not yet assessed
-
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study ↗The Lancet Haematology · 2018 · PMID 30072146not yet assessed
-
[Development of digital PCR molecular tests for clinical practice: principles, practical implementation and recommendations]. ↗PubMed · 2018 · PMID 30226193not yet assessed
-
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes ↗Haematologica · 2018 · PMID 30287621not yet assessed
-
<scp>CD</scp>13 expression in B cell malignancies is a hallmark of plasmacytic differentiation ↗British Journal of Haematology · 2018 · PMID 30198568not yet assessed
-
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization ↗Haematologica · 2018 · PMID 30573508not yet assessed
-
Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes ↗Oncotarget · 2018 · PMID 29599920not yet assessed
-
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia ↗Clinical Chemistry and Laboratory Medicine (CCLM) · 2018 · PMID 30267623not yet assessed
-
Diagnosis and Prognosis: Molecular ↗Hematologic malignancies · 2018not yet assessed
-
Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes ↗SSRN Electronic Journal · 2018not yet assessed
-
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia ↗Leukemia · 2017 · PMID 28914261not yet assessed
-
Dyserythropoiesis of myelodysplastic syndromes ↗Current Opinion in Hematology · 2017 · PMID 28072603not yet assessed
-
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling ↗Leukemia · 2017 · PMID 28972593not yet assessed
-
not yet assessed
-
Diversity of TP53 Mutations in CLL: Retrospective Analysis of 450 Mutations from the French Innovative Leukemia Organization (FILO) Group ↗Clinical Lymphoma Myeloma & Leukemia · 2017not yet assessed
-
not yet assessed
-
not yet assessed
-
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? ↗Haematologica · 2016 · PMID 27056923not yet assessed
-
Response to 5‐azacytidine in a patient with <i>TET2</i>‐mutated angioimmunoblastic T‐cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV‐positive large B‐cell lymphoma ↗Hematological Oncology · 2016 · PMID 27353473not yet assessed
-
An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia ↗Clinical Cancer Research · 2016 · PMID 27881579not yet assessed
-
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes ↗Blood · 2016 · PMID 27856460not yet assessed
-
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis ↗Oncotarget · 2016 · PMID 26910909not yet assessed
-
not yet assessed
-
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des MyélodysplasiesHAL (Le Centre pour la Communication Scientifique Directe) · 2016not yet assessed
-
Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q) ↗Blood · 2016not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion ↗Leukemia · 2015 · PMID 26500139not yet assessed
-
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia ↗Science Advances · 2015 · PMID 26601252not yet assessed
-
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome ↗Blood Cancer Journal · 2015 · PMID 25555161not yet assessed
-
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion ↗Blood · 2015 · PMID 26626993not yet assessed
-
French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment ↗Hématologie · 2015not yet assessed
-
Mutations of ETNK1 in aCML and CMML ↗Blood · 2015 · PMID 25593331not yet assessed
-
ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: An International Study of 466 Patients ↗Clinical Lymphoma Myeloma & Leukemia · 2015not yet assessed
-
French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group ↗Hématologie · 2015not yet assessed
-
not yet assessed
-
Erratum: Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome ↗Blood Cancer Journal · 2015not yet assessed
-
104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY ↗Leukemia Research · 2015not yet assessed
-
148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS ↗Leukemia Research · 2015not yet assessed
-
109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS ↗Leukemia Research · 2015not yet assessed
-
159 CSNK1A1 IS NORMALLY EXPRESSED AND UNMUTATED IN MDS PATIENTS WITHOUT DEL(5Q) BEFORE AND UNDER TREATMENT WITH LENALIDOMIDE ↗Leukemia Research · 2015not yet assessed
-
not yet assessed
-
Figure S1 - Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket ↗Figshare · 2015not yet assessed
-
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients ↗Leukemia · 2014 · PMID 24695057not yet assessed
-
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp>ayo <scp>C</scp>linic‐<scp>F</scp>rench <scp>C</scp>onsortium <scp>S</scp>tudy ↗American Journal of Hematology · 2014 · PMID 25195656not yet assessed
-
Efficacy <scp>of</scp> 5‐Azacytidine in a <i><scp>TET</scp>2</i> mutated angioimmunoblastic T cell lymphoma ↗British Journal of Haematology · 2014 · PMID 25312805not yet assessed
-
A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages ↗Leukemia · 2014 · PMID 24434863not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia ↗Journal of Clinical Oncology · 2013 · PMID 23690417not yet assessed
-
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia ↗Blood · 2013 · PMID 24014241not yet assessed
-
Clonal architecture of chronic myelomonocytic leukemias ↗Blood · 2013 · PMID 23319568not yet assessed
-
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders ↗Blood · 2013 · PMID 24047651not yet assessed
-
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias ↗Leukemia · 2013 · PMID 23443343not yet assessed
-
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes ↗Leukemia · 2013 · PMID 23765225not yet assessed
-
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine ↗Leukemia · 2013 · PMID 24192812not yet assessed
-
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia ↗Leukemia · 2013 · PMID 23774674not yet assessed
-
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes ↗Best Practice & Research Clinical Haematology · 2013 · PMID 24507812not yet assessed
-
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) ↗Leukemia · 2013 · PMID 23434730not yet assessed
-
Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket ↗PLoS ONE · 2013 · PMID 23637779not yet assessed
-
Epigenetic Control of NF-κB-Dependent <i>FAS</i> Gene Transcription during Progression of Myelodysplastic Syndromes ↗Molecular Cancer Research · 2013 · PMID 23604035not yet assessed
-
not yet assessed
-
A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. ↗Journal of Clinical Oncology · 2013not yet assessed
-
P-004 SETBP1 mutations in 658 patients with myeldodysplastic syndromes, chronic myelomonocytic leukemia and secondary AML ↗Leukemia Research · 2013not yet assessed
-
P-233 Promoter methylation abrogates of NFκB-mediated FAS gene transcription during progression of myelodysplastic syndromes ↗Leukemia Research · 2013not yet assessed
-
P-133 A single nucleotide polymorphism in CRBN gene as a biomarker of response to treatment with lenalidomide in MDS without del5q ↗Leukemia Research · 2013not yet assessed
-
O-007 BCOR and BCORL1 mutations in myelodysplasia: Prevalence, prognosis and clonal hierarchy ↗Leukemia Research · 2013not yet assessed
-
P-071 Flow cytometric detection of dyserythropoiesis is a sensitive and powerful tool for myelodysplastic syndrome diagnosis ↗Leukemia Research · 2013not yet assessed
-
P-245 Effector CD4+CD45RA-CD25brightFoxp3bright regulatory T cells (eTregs) are significantly increased in chronic myelomonocytic leukemia (CMML) with TET2 mutations ↗Leukemia Research · 2013not yet assessed
-
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes ↗Blood · 2012 · PMID 22343920not yet assessed
-
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia ↗Blood · 2012 · PMID 22438255not yet assessed
-
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia ↗Oncotarget · 2012 · PMID 23327988not yet assessed
-
Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML) ↗Blood · 2012not yet assessed
-
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes ↗Leukemia Research · 2012 · PMID 23153525not yet assessed
-
Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis ↗Clinical Lymphoma Myeloma & Leukemia · 2012 · PMID 23246161not yet assessed
-
Mutations des gènes impliqués dans l’épissage dans les hémopathies malignes humaines ↗médecine/sciences · 2012 · PMID 22642991not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Epigenetic Down-Regulation of NFkB-Mediated FAS Gene Transcription During Progression of Myelodysplastic Syndromes ↗Blood · 2012not yet assessed
-
BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes ↗Blood · 2012not yet assessed
-
not yet assessed
-
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias ↗Leukemia · 2011 · PMID 21494260not yet assessed
-
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications ↗Leukemia · 2011 · PMID 22064355not yet assessed
-
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes ↗Blood · 2011 · PMID 22160620not yet assessed
-
TET2 mutations in secondary acute myeloid leukemias: a French retrospective study ↗Haematologica · 2011 · PMID 21508122not yet assessed
-
Leukemic phase of follicular lymphomas: an atypical presentation ↗Leukemia & lymphoma/Leukemia and lymphoma · 2011 · PMID 21585282not yet assessed
-
306 Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias ↗Leukemia Research · 2011not yet assessed
-
44 FAS gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes ↗Leukemia Research · 2011not yet assessed
-
Syndromes myélodysplasiques : actualités clinico-biologiques ↗Revue Francophone des Laboratoires · 2011not yet assessed
-
IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias, ↗Blood · 2011not yet assessed
-
305 TET2 and IDH1/2 mutations in secondary acute myeloid leukemias: A French retrospective study ↗Leukemia Research · 2011not yet assessed
-
239 NF-κB regulates FAS gene expression in myelodysplastic syndromes ↗Leukemia Research · 2011not yet assessed
-
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms ↗Leukemia · 2010 · PMID 20376084not yet assessed
-
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission ↗Blood · 2010 · PMID 20489055not yet assessed
-
Genetic typing of <i>CBL</i>, <i>ASXL1</i>, <i>RUNX1</i>, <i>TET2</i> and <i>JAK2</i> in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia ↗British Journal of Haematology · 2010 · PMID 20955399not yet assessed
-
Chromosomal abnormalities in transformed Ph‐negative myeloproliferative neoplasms are associated to the transformation subtype and independent of <i>JAK2</i> and the <i>TET2</i> mutations ↗Genes Chromosomes and Cancer · 2010 · PMID 20629097not yet assessed
-
Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS ↗Blood · 2010not yet assessed
-
not yet assessed
-
Biologie des syndromes myélodysplasiques ↗Hématologie · 2010not yet assessed
-
not yet assessed
-
Mutation in <i>TET2</i> in Myeloid Cancers ↗New England Journal of Medicine · 2009 · PMID 19474426not yet assessed
-
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) ↗Blood · 2009 · PMID 19666869not yet assessed
-
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia ↗Haematologica · 2009 · PMID 19797729not yet assessed
-
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia ↗Blood · 2009 · PMID 19864642not yet assessed
-
Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias ↗Leukemia · 2009 · PMID 19710701not yet assessed
-
Erythropoietin Down-Regulates Stem Cell Factor Receptor (Kit) Expression in the Leukemic Proerythroblast: Role of Lyn Kinase ↗PLoS ONE · 2009 · PMID 19492092not yet assessed
-
Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML). ↗Blood · 2009not yet assessed
-
Physiopathologie des syndromes myélodysplasiques ↗Revue Francophone des Laboratoires · 2009not yet assessed
-
not yet assessed
-
C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS ↗Leukemia Research · 2009not yet assessed
-
P051 TET2 is a tumor suppressor gene targeted in myeloid disorders ↗Leukemia Research · 2009not yet assessed
-
C020 Prevalence of TET2 mutations in MDS ↗Leukemia Research · 2009not yet assessed
-
P-ERK1/2 Is a Predictive Factor of Response to ESA Treatment in Myelodysplastic Syndromes. ↗Blood · 2009not yet assessed
-
not yet assessed
-
Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation ↗Blood · 2006 · PMID 17132716not yet assessed
-
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate ↗Oncogene · 2006 · PMID 17173066not yet assessed
-
From Mice to Human: The “Two-Hit Model” of Leukemogenesis ↗Cell Cycle · 2006 · PMID 16582609not yet assessed
-
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice ↗Cancer Cell · 2005 · PMID 16338660not yet assessed
-
Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene ↗Oncogene · 2005 · PMID 16247441not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
Merged across profiles sharing this ORCID where present. See every “Kosmider O” paper on PubMed ↗